ALNY News and Press, Alnylam Pharmaceuticals Inc. From 06/24/24

2024-06-24 18:30:03 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for ALNY on June 24, 2024 04:25PM ET. The previous analyst recommendation was Equal-Weight. ALNY was trading at $222.9 at issue of the analyst recommendation. The overall analyst consensus :...

A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.7% to $118.11 on volume of 457,565,587 shares Agrify Corporation (AGFY) rose 68.7% to $0.4251 on volume of 291,898,257 shares Ginkgo Bioworks Holdings Inc. Class A (DNA) fell 13.7% to $0.3662 on volume...

2024-06-24 16:00:09 ET Andrew Galler from Morgan Stanley issued a price target of $250.00 for ALNY on 2024-06-24 12:28:00. The adjusted price target was set to $250.00. At the time of the announcement, ALNY was trading at $224.7. The overall price target consensus is at ...

2024-06-24 13:25:16 ET More on Sanofi Sanofi's Immunology Business Is Doing A Lot Of Heavy Lifting Sanofi: A Leader In Life-Saving Vaccines And Treatments Sanofi Q1: Wait And See For Now (Downgrade) Innate falls on updated phase 1/2 data on blood cancer asset...

2024-06-24 13:00:05 ET Patrick Trucchio from H.C. Wainwright issued a price target of $400.00 for ALNY on 2024-06-24 11:29:00. The adjusted price target was set to $400.00. At the time of the announcement, ALNY was trading at $227.05. The overall price target consensus i...

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is one of today's top gainers. The company's shares have moved 37.68% on the day to $228.13. Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic ...

2024-06-24 11:37:31 ET Summary HELIOS-B Phase III study of Amvuttra in patients with ATTR-CM succeeded across all metrics, showing significant benefits in both the combined study population and monotherapy groups. Amvuttra showed strong efficacy in reducing all-cause mortality and...

2024-06-24 11:30:03 ET BMO Capital analyst issues OUTPERFORM recommendation for ALNY on June 24, 2024 09:18AM ET. The previous analyst recommendation was Outperform. ALNY was trading at $217.4775 at issue of the analyst recommendation. The overall analyst consensus : BUY...

2024-06-24 11:03:25 ET Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) opened more than 30% up on Monday after reporting promising results from a late-stage trial of its heart drug. Shares of the biopharmaceutical company are now trading at a year-to-date high of $220. Why is it sign...

A look at the top 10 most actives in the United States Agrify Corporation (AGFY) rose 164.2% to $0.6658 on volume of 125,460,313 shares NVIDIA Corporation (NVDA) fell 2.9% to $122.88 on volume of 51,163,891 shares Crown Electrokinetics Corp. (CRKN) fell 0.3% to $0.04097 on volume of 44,45...